23770-07-2 Usage
Uses
Used in Pharmaceutical Industry:
1-benzyl-5-Methylpyrrolidin-3-one is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and medications.
Used in Agrochemical Industry:
1-benzyl-5-Methylpyrrolidin-3-one is used as a precursor in the synthesis of agrochemicals to help create effective products for agricultural applications.
Used in Organic Synthesis:
1-benzyl-5-Methylpyrrolidin-3-one is used as a building block in organic synthesis for the preparation of a variety of compounds, showcasing its utility in creating diverse chemical structures.
Used in Medicinal and Scientific Research:
1-benzyl-5-Methylpyrrolidin-3-one is used in research for its potential biological activities, such as antimicrobial and anti-inflammatory properties, making it a valuable compound for exploring new therapeutic avenues and understanding its mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 23770-07-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,7,7 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 23770-07:
(7*2)+(6*3)+(5*7)+(4*7)+(3*0)+(2*0)+(1*7)=102
102 % 10 = 2
So 23770-07-2 is a valid CAS Registry Number.
23770-07-2Relevant academic research and scientific papers
BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS
-
Page/Page column 24, (2010/12/29)
The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1 ), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.
Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
-
, (2008/06/13)
The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-α inhibitors.
